Pemphigus vulgaris severe: Case report of successful treatment with plasmapheresis and rituximab
Keywords:
Pemphigus, rituximab, plasmapheresis.Abstract
Autoimmune blistering diseases are classified according to the level of blister formation in intraepidermal (pemphigus group) and sub-epidermal (pemphigoid group). In the pemphigus group there are six main variants, being the most common pemphigus vulgaris in this group. The prognosis of the disease has gradually improved since the use of systemic steroids and immunosuppressants, but the adverse effects associated with prolonged use of these drugs remains a major cause of morbidity and mortality in these patients. This has led to the development of new therapies aimed at different points in the pathogenesis of the disease. We present the case of a 31-years old male patient with a clinical history of several years pemphigus vulgaris resistant to conventional therapy with systemic steroids and steroid sparing that responded satisfactorily to treatment with plasmapheresis rituximab.
Author Biographies
Claudia Marcela Gaviria
Médica, residente de Dermatología, Universidad CES, Medellín, Colombia
Lina María Colmenares
Médica dermatóloga; docente de Dermatología, Universidad CES, Medellín, Colombia
References
2. Ruocco V, Ruocco E, Lo Schiavo A, Brunetti G, Guerrera LP, Wolf R. Pemphigus: Etiology, pathogenesis, and inducing or triggering factors: Facts and controversies. Clin Dermatol. 2013;31:374-81.
3. Ruocco E, Wolf R, Ruocco V, Brunetti G, Romano F, Lo Schiavo A. Pemphigus: Associations and management guidelines: Facts and controversies. Clin Dermatol. 2013;31:382-90.
4. Frew JW, Martin LK, Murrell DF. Evidence-based treatments in pemphigus vulgaris and pemphigus foliaceus. Dermatol Clin. 2011;29:599-606.
5. Yeh SW, Sami N, Ahmed RA. Treatment of pemphigus vulgaris: Current and emerging options. Am J Clin Dermatol. 2005;6:327-42.
6. Schmidt E, Goebeler M, Zillikens D. Rituximab in severe pemphigus. Ann N Y Acad Sci. 2009;1173:683-91.
7. Zakka LR, Shetty SS, Ahmed AR. Rituximab in the treatment of pemphigus vulgaris. Dermatol Ther. 2012;2:17.
8. Carr DR, Heffernan MP. Off-label uses of rituximab in dermatology. Dermatol Ther. 2007;20:277-87.
9. Hertl M, Zillikens D, Borradori L, Bruckner-Tuderman L, Burckhard H, Eming R, et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. 2008;6:366-73.
10. Kanwar AJ, Vinay K. Rituximab in pemphigus. Indian J Dermatol Venereol Leprol. 2012;78:671-6.
How to Cite
Downloads
Downloads
Published
How to Cite
Issue
Section
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
